Unrelated donor (URD) BMT is being performed more often for children with non-malignant life-threatening disorders. As GVHD is of no possible benefit in this patient group, T-cell depletion (TCD) may be used to minimize the risk of GVHD. Non-engraftment or graft failure is more common among BMT recipients who have received minimal prior chemotherapy, and among patients receiving TCD grafts. A second BMT may be required for such patients who reject their first graft. After rejection of the first BMT, TCD is unlikely to be used for a second procedure, but GVHD is still a concern in this patient population. In this situation, cord blood transplantation (CBT) may be an option, although CBT has itself been associated with an increased risk of graft rejection. We report two children with non-malignant conditions who successfully engrafted following unrelated CBT after failing to engraft following T-depleted unrelated donor BMT.
Patient 1 was an asymptomatic 16-month boy with metachromatic leukodystrophy (MLD). An URD matched at HLA A, B and DRB1, DQB1 with a C mismatch was located. He was conditioned with BUCY and antithymocyte globulin (ATG). The bone marrow was treated by TCD using sheep red blood cell rosetting, and he received a transfusion of 1.5 Â 10 8 /kg nucleated cells, 1.1 Â 10 6 /kg CD34 cells and 3.0 Â 10 5 /kg CD3 cells. Prophylaxis against GVHD consisted of the TCD and CsA. He failed to engraft, received an autologous reinfusion of bone marrow and then recovered his count. An immune-mediated rejection process was suspected clinically and a second donor was also considered unsuitable because they shared the same HLA C antigen with the original donor that was disparate from the patient's HLA C antigen. An unrelated cord mismatched at one HLA A antigen was identified. Subsequently, it was shown that this cord unit was also matched at the HLA C locus.
The patient was reconditioned using CY, TBI and ATG. The cord blood contained 5.4 Â 10 7 /kg total nucleated cells with 3.24 Â 10 5 /kg CD34 cells. CsA and methylprednisolone were given for GVHD prophylaxis. He engrafted successfully and chimerism studies from day 30 to 3 years post BMT confirmed 100% donor chimerism.
Patient 2, aged 4 years, presented with Fanconi's anaemia. He developed significant side effects secondary to androgen therapy, remained pancytopenic and had lifethreatening septicemia. An URD matched at HLA A, B, C, DRB1, DQB1 was identified and he was conditioned with CY, TBI and ATG. CliniMacs was used for TCD, so that 5.8 Â 10 6 /kg nucleated cells (5.2 Â 10 6 /kg CD34 cells) were infused, with T-cell addback to give a total CD3 infusion of 5.44 Â 10 5 /kg. GVHD prophylaxis consisted of the partial TCD and CsA. After early engraftment and signs of GVHD, he became aplastic and showed returning recipient chimerism that could not be salvaged with a donor T-cell infusion on day 55. It was felt inadvisable to use the same donor again. 1 A cord unit matched at HLA A, B and DRB1 loci was identified and he was reconditioned with fludarabine, TBI and ATG. The cord included a total nucleated cell count of 3.4 Â 10 7 /kg, with 2.4 Â 10 5 /kg CD34 cells. GVHD prophylaxis was with CsA and mycophenolate. He rapidly engrafted and developed some skin GVHD. He had limited chronic GVHD treated with CsA and prednisolone until 13 months post-CBT and showed progressive recovery of immune function during the second year post-HCT.
We have reported two paediatric patients with nonmalignant conditions where unrelated partially TCD BMTs were followed by failed engraftment. Subsequent CBT led to engraftment and a successful outcome. Successful unrelated CBT following graft failure of a prior unrelated bone marrow transplant has not been reported in the literature. There is one case report of successful matched sibling CBT following late graft failure of a mismatched parental graft. 2 There were reasons to anticipate difficulties with engraftment with CBT as a second procedure for these two patients. CBT has been associated with a risk of graft failure of around 20% and Fanconi's anaemia has been specifically associated with graft failure following CBT. 3 Second transplants of any type do not seem to carry a higher rate of non-engraftment overall, but this is usually in the absence of any TCD that may have been used in the first graft. 4 After successfully recovering from their first graft, both sets of parents of these patients were keen to attempt a second procedure, but also concerned of the risk of GVHD if we proceeded to a second URD BMT without TCD. In this situation, the reduced rate of GVHD seen in unrelated CBT vs BMT may offer a potential solution. Where the disease may progress quickly, as in the neurodegenerative disorders such as MLD, CBT may be a faster option than finding another BM donor. The initial interval from initiation of search to BMT had taken 7 months and, even with proceeding direct to CBT, the delay between first and second BMT was 5 months. Thus, one of the advantages of an UCBT is being able to perform the procedure more rapidly, and this may be as important or even more important when a second procedure is required. 
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